Add BrightSurf on Google Email

Search results for “Oncology”

1,000+ results for "Oncology"

Long-term results from Testicular Cancer treatment are positive, study shows

A recent study published in the Journal of Clinical Oncology found that combining different chemotherapy drugs improves testicular cancer's treatability and often curability, even after first-line treatment fails. The study showed a nearly 80% response rate and no significant drop-off in survival over 10 years.

SourceUniversity College Cork·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateJul 19, 2024

Lancet Oncology publication establishes imaging guidelines for head and neck cancers, a step toward practice change

The study establishes criteria for identifying extranodal extension on imaging, allowing radiologists to make accurate calls and provide patients with less invasive treatments. This shift towards practice change has the potential to reduce side effects and improve outcomes for patients with HPV-associated head and neck cancers.

SourceUniversity of Oklahoma·JournalThe Lancet Oncology·TypeSurvey·DateJul 16, 2024

Study supports precision radiation therapy in lung cancer

Researchers at MD Anderson Cancer Center found fewer side effects with intensity-modulated radiotherapy (IMRT), with similar survival outcomes compared to 3D-CRT. The study validated heart exposure as an important radiation planning objective, revealing better five-year overall and progression-free survival rates for IMRT.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalJAMA Oncology·TypeRandomized controlled/clinical trial·DateJun 27, 2024

ASTRO issues clinical guideline on radiation therapy for patients with HPV-related throat cancer

The American Society for Radiation Oncology (ASTRO) has published an updated clinical guideline for treating patients with HPV-related oropharyngeal squamous cell carcinoma. The guideline emphasizes the importance of tailored radiation strategies to maximize patient survival while minimizing side effects. It provides recommendations fo...

SourceAmerican Society for Radiation Oncology·JournalPractical Radiation Oncology·TypeSystematic review·DateJun 18, 2024

NRG Oncology abstract considered “best of ASCO” for 2024 shows difference in outcomes for node-negative versus node-positive pancreatic cancer patients when adding chemoradiation to systemic therapy

The NRG-RTOG 0848 clinical study found that adding chemoradiation to adjuvant systemic therapy improves overall survival for node-negative pancreatic cancer patients, but not for those with node-positive disease. Disease-free survival was also improved in both groups.

Many more women in oil-rich Gulf countries battle with breast cancer as the disease develops localized pathological features, study says

A study published in Frontiers in Oncology reveals breast cancer incidence has surged in oil-rich Gulf countries, with unique clinical and pathological features. The disease is attributed to a combination of menstrual cycle, hereditary factors, weaning children earlier than expected, hormonal treatment, obesity, and use of contraceptives.

SourceUniversity of Sharjah·JournalFrontiers·TypeObservational study·DateJun 3, 2024

ASCO: MD Anderson’s Sharon Giordano and Richard Gorlick honored as 2024 Special Awards Recipients

Sharon Giordano and Richard Gorlick will be honored with Special Awards at the 2024 American Society of Clinical Oncology Annual Meeting for their dedication to improving cancer treatment and patient outcomes. Their research has made significant contributions to the field of oncology, with a focus on breast cancer and pediatric oncology.

Features of bloodstream infection among immunocompromised oncology patients presenting to the emergency department with fever

The study found a 5.7% blood culture positive rate among eligible Hem-Onc patients, with 56% having an absolute neutrophil count greater than 500 µL at presentation. Gram-positive organisms were the most common isolates, highlighting the diversity of bloodstream infection causes in this patient population.

SourceXia & He Publishing Inc.·JournalOncology Advances·DateMay 23, 2024

ASTRO clinical guideline on radiation therapy for bone metastases emphasizes patient-centered care

The updated clinical guideline recommends multiple dose-fractionation schemes to relieve pain and symptoms of bone and spine lesions. Advanced radiation techniques like intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT) are now routine clinical care for many patients.

SourceAmerican Society for Radiation Oncology·JournalPractical Radiation Oncology·DateMay 23, 2024

Hypofractioned post-prostatectomy radiotherapy new acceptable practice standard based on NRG Oncology trial findings

A new acceptable practice standard for hypofractionated post-prostatectomy radiotherapy has been established based on the NRG Oncology trial findings. The study showed that HYPORT was non-inferior to COPORT in terms of late GI or GU toxicity, with greater short-term GI toxicity associated with HYPORT but resolving at 6 months following...

SourceNRG Oncology·JournalJAMA Oncology·DateMar 18, 2024

Magnetic resonance surveillance reduces mortality in women at high risk of BRCA1 breast cancer

A study published in JAMA Oncology found that MRI monitoring in women with BRCA1 mutations significantly reduces breast cancer mortality without the need for preventive mastectomy. The research included data from 2,488 women and showed a notable decrease in mortality rate among participants.

SourceInstitut de Recerca Sant Pau (Sant Pau Research Institute)·JournalJAMA Oncology·TypeObservational study·DateMar 1, 2024

Significant proportion of cancer drugs lack proof of added benefit

A study found that over half of cancer drugs approved through expedited pathways recover research and development costs within three years, despite lacking proof of added benefit. The researchers emphasize the need for better alignment between regulatory and reimbursement processes to promote effective drug development.

SourceBMJ Group·JournalThe BMJ·TypeObservational study·DateFeb 28, 2024

Elenagen, a novel DNA immunotherapy for the deadliest form of ovarian cancer, delays disease progression

Researchers created Elenagen, a novel DNA immunotherapy for deadly ovarian cancer, which significantly enhances standard chemotherapy and provides clinical benefits. The study shows that Elenagen delays disease progression in patients with stage III and IV platinum-resistant ovarian cancer.

SourceCureLab Oncology Inc.·JournalFrontiers in Oncology·TypeRandomized controlled/clinical trial·DateFeb 22, 2024

Evaluating the performance of AI-based large language models in radiation oncology

A new study evaluates AI algorithms for autocontouring prior to radiotherapy in head and neck cancer. OpenAI's GPT-4-turbo demonstrated the best performance, while Llama-2 models underperformed. The study highlights the potential of generative AI to revolutionize radiation oncology education and practice.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalAI in Precision Oncology·TypeExperimental study·DateFeb 8, 2024

NRG Oncology and the University of Pittsburgh demonstrate that a machine learning model predicts oxaliplatin benefit using data from two NSABP clinical trials

A new machine learning model, COLOXIS, uses data from two NSABP clinical trials to predict which colon cancer patients will benefit from the addition of oxaliplatin. The model shows that patients with a signature-positive prediction can derive benefit from oxaliplatin, while those with a signature-negative prediction do not.

SourceNRG Oncology·JournalJournal of Clinical Oncology·DateFeb 6, 2024

City of Hope Children’s Cancer Center, Children’s Oncology Group conduct largest clinical trial seeking to prevent heart failure among childhood cancer survivors

A Phase 2B clinical trial, led by City of Hope, found that carvedilol may improve heart health markers and reduce the risk of heart failure in childhood cancer survivors. The study suggests that carvedilol could benefit long-term survivors and those who are highly adherent to the treatment.

SourceCity of Hope·JournalThe Lancet Oncology·TypeRandomized controlled/clinical trial·DateJan 9, 2024

Lung nodule program provides benefits patients ineligible for lung cancer screening

A study published in the Journal of Thoracic Oncology found that adopting a lung nodule program can increase early lung cancer detection for patients not eligible for traditional screening. The study revealed significant differences in stage at diagnosis and overall survival rates between young, elderly, and screened cohorts.

SourceInternational Association for the Study of Lung Cancer·JournalJournal of Thoracic Oncology·TypeObservational study·DateDec 18, 2023

The Lancet Oncology: Risk of dying from cancer in some poorer districts of England over 70% higher than wealthy districts, study suggests

A recent study published in The Lancet Oncology found that the risk of dying from cancer in some poorer districts of England is over 70% higher than in wealthier areas. The study used death records to estimate the risk of dying from various cancers in each district, highlighting significant inequalities in cancer mortality across diffe...

SourceThe Lancet·JournalThe Lancet Oncology·TypeObservational study·DateDec 11, 2023

Oncology researchers raise ethics concerns posed by patient-facing Artificial Intelligence

Bioethics researchers at Dana-Farber Cancer Institute warn that patient-facing AI can depersonalize care and erode relationships between patients and caregivers. The authors advocate for principles such as human dignity, patient autonomy, and regulatory oversight to ensure AI-driven healthcare is ethically sound and equitable.

SourceDana-Farber Cancer Institute·JournalJCO Oncology Practice·DateNov 3, 2023

St. Jude refines definition and hones treatment of hyperdiploid leukemia

Researchers at St. Jude Children's Research Hospital refined the definition of hyperdiploidy in childhood B-cell acute lymphoblastic leukemia (B-ALL), using DNA index to predict patient outcomes. The study found that a simpler system captures a significant proportion of patients with excellent prognoses, and that individual chromosome ...

SourceSt. Jude Children's Research Hospital·JournalJournal of Clinical Oncology·DateSep 20, 2023

Cancer organizations recommend mindfulness-based interventions to treat anxiety and depression in patients

The Society for Integrative Oncology (SIO) and the American Society of Clinical Oncology (ASCO) recommend mindfulness-based stress reduction, meditation, and mindful movement to treat anxiety and depression symptoms in cancer patients. These interventions have strong evidence supporting their benefits.

SourceThe Reis Group·JournalJournal of Clinical Oncology·TypeLiterature review·DateAug 15, 2023

Science backs mind-body tools like meditation and music for cancer-related anxiety

National guidelines recommend mindfulness meditation, yoga, and music therapy for cancer patients experiencing anxiety and depression. The guidelines are based on strong evidence from clinical studies, providing a comprehensive approach to managing these common side effects of cancer treatment.

SourceUniversity of Rochester Medical Center·JournalJournal of Clinical Oncology·TypeLiterature review·DateAug 15, 2023

HKUMed in collaboration with the Hong Kong Sanatorium & Hospital, establishes the positive clinical impact of the Multidisciplinary Molecular Tumour Board among patients with advanced solid cancer in the era of Precision Cancer Medicine

The Multidisciplinary Molecular Tumour Board (MTB) has been shown to improve treatment response rates for patients with advanced solid cancer, with 64% of patients benefiting from the MTB-guided approach. The board provides a systematic precision oncology strategy for treatment selection, combining expertise in multiple disciplines.

SourceThe University of Hong Kong·JournalThe Lancet Regional Health - Western Pacific·TypeExperimental study·DateJul 4, 2023

New understanding of why kidney cancers become metastatic discovered by MD Anderson researchers

Researchers at MD Anderson Cancer Center have engineered a new model of aggressive renal cell carcinoma, highlighting molecular targets and genomic events that trigger chromosomal instability. The loss of interferon receptor genes plays a pivotal role in allowing cancer cells to become tolerant of chromosomal instability.

Patient-reported outcomes from an NRG Oncology study of androgen deprivation therapy with dose-escalated radiotherapy for intermediate-risk prostate cancer show no clinically meaningful differences in scores at one year post-treatment

A recent study published in Journal of Clinical Oncology found that dose-escalated radiotherapy with short-term androgen deprivation therapy showed no significant impact on urinary or bowel quality of life for men with intermediate-risk prostate cancer. However, the treatment did significantly decrease hormone and sexual quality of lif...

SourceNRG Oncology·JournalJournal of Clinical Oncology·DateApr 27, 2023

NRG Oncology study results confirm conventional external beam radiotherapy should remain standard of care in treating localized vertebral metastases of the spine

The NRG Oncology study found that stereotactic radiosurgery was not superior to conventional external beam radiotherapy in terms of pain response, and even showed worse pain response at 3 months. Conventional radiotherapy remained effective with a 50-60% pain relief rate, but only lasting four months.

SourceNRG Oncology·JournalJAMA Oncology·DateApr 27, 2023

NRG Oncology trial does not improve overall survival, but shows improvements in several clinical outcomes for men with intermediate-risk prostate cancer

The study found that dose-escalated radiotherapy with short-term androgen deprivation therapy improved rates of biochemical failure, distant metastases, and prostate cancer-specific mortality. However, the trial did not meet its primary endpoint of improving overall survival for men with intermediate-risk prostate cancer.

SourceNRG Oncology·JournalJournal of Clinical Oncology·DateApr 27, 2023

Integrative neuro-oncology for brain tumor patients

Neurologist Soma Sengupta introduces the concept of integrative neuro-oncology, combining conventional treatments with alternative therapies to enhance patient well-being. Her approach prioritizes the unique needs of brain tumor patients and their caregivers, promoting a holistic understanding of medicine.

SourceUniversity of Cincinnati·JournalJournal of Neuro-Oncology·TypeCommentary/editorial·DateApr 26, 2023